Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to gamma-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“irradiation can also increase tumor antigenicity through enriching the pool of antigenic peptides”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reits et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“folding the HLA-A1 heavy chain with peptides CGI-51(206–215), MSH6(469–478), and F-box protein Fbl7(335–362) and human β2m as described (51).”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
Schubert, U., Antón, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., & Bennink, J. R. (2000) · Nature · doi:10.1038/35008096 · Cited by 1,536
Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags
Mann, M., & Wilm, M. (1994) · Analytical Chemistry · doi:10.1021/ac00096a002 · Cited by 1,468
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 3×
“This is probably not due only to up-regulation of MHC class I expression because mTOR activation will have more general eff ects on protein expression including up-regulation of Fas, ICAM-1 (38), and interferon expression (33, 34).”
Background
Research works printed but not linked: 5
- 2000, Oncology (Huntingt), 14, 741
- 1988, Nippon Igaku Hoshasen Gakkai Zasshi., 48, 1572
- 2000, Anticancer Res., 20, 3375
- 2002, Cancer Res., 62, 1462
- 1991, Cancer Res., 51, 3657
Cited by
Items 801–900 of 1,000
Neoadjuvant therapy of locally/regionally advanced melanoma
Khunger, A., Buchwald, Z. S., Lowe, M., Khan, M. K., Delman, K. A., & Tarhini, A. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919866959 · Cited by 29
Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer
Plavc, G., Jesenko, T., Oražem, M., & Strojan, P. (2020) · Cancers · doi:10.3390/cancers12113197 · Cited by 29
Jin, Y., Jiang, J. F., Mao, W. B., Bai, M., Chen, Q., & Zhu, J. Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216858 · Cited by 28
Glynne‐Jones, R., Hall, M., & Nagtegaal, I. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102104 · Cited by 28
Heumann, T. R., & Azad, N. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09981-3 · Cited by 28
Perrin, J., Capitao, M., Allard, M., Chouin, N., Gouard, S., Marionneau‐Lambot, S., Louvet, C., Donnadieu, E., Bruchertseifer, F., Morgenstern, A., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.10.013 · Cited by 28
Advancements in melanoma immunotherapy: the emergence of Extracellular Vesicle Vaccines
He, G., Li, Y., Zeng, Y., Zhang, Y., Jiang, Q., Zhang, Q., Zhu, J., & Gong, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02150-9 · Cited by 28
Radiation meets immunotherapy – a perfect match in the era of combination therapy?
Soukup, K., & Wang, X. (2015) · International Journal of Radiation Biology · doi:10.3109/09553002.2014.995383 · Cited by 28
Tomihara, K., Fuse, H., Heshiki, W., Takei, R., Zhang, B., Arai, N., Nakamori, K., & Noguchi, M. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.01.013 · Cited by 28
Fadilah, S. A. W. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1313-0 · Cited by 28
Impact of radiation therapy on the immunological tumor microenvironment
Guilbaud, E., Naulin, F., Meziani, L., Deutsch, É., & Galluzzi, L. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.001 · Cited by 28
Wang, X., & Jing, J. (2025) · MedComm · doi:10.1002/mco2.70346 · Cited by 27
Wang, L., Yao, R., Zhang, L., Fan, C., Ma, L., & Liu, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.01.010 · Cited by 27
Ye, H., Pang, H., Shi, X., Ren, P., Huang, S., Yu, H., Wu, J., & Lin, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657024 · Cited by 27
The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
Wen, L., Tong, F., Zhang, R., Chen, L., Huang, Y., & Dong, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.799957 · Cited by 27
Shen, P. F., Qiao, B., Jin, N., & Wang, S. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01293-9 · Cited by 27
Hartmann, L., Osen, W., Eichmüller, O. L., Kordaß, T., Furkel, J., Dickes, E., Reid, C., Debus, J., Brons, S., Abdollahi, A., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215928 · Cited by 27
Radiotherapy and Toll-Like Receptor Agonists
Marabelle, A., Filatenkov, A., Sagiv-Barfi, I., & Kohrt, H. E. K. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.006 · Cited by 27
Werner, L. R., Kler, J. S., Gressett, M. M., Riegert, M., Werner, L. K., Heinze, C. M., Kern, J. G., Abbariki, M., Erbe, A. K., Patel, R. B., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.08.016 · Cited by 27
Applying Precision Oncology Principles in Radiation Oncology
Kamran, S. C., & Mouw, K. W. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00034 · Cited by 27
In Vivo Irradiation of Mice Induces Activation of Dendritic Cells
Persa, E., Szatmári, T., Sáfrány, G., & Lumniczky, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082391 · Cited by 27
Tsoutsou, P. P., Zaman, K., Lluesma, S. M., Cagnon, L., Kandalaft, L. E., & Vozenin, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00609 · Cited by 27
Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery
Alfonso, J. C. L., Poleszczuk, J., Walker, R., Kim, S., Pilon‐Thomas, S., Conejo-Garcia, J. R., Soliman, H. H., Czerniecki, B. J., Harrison, L. B., & Enderling, H. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00075 · Cited by 27
Corrao, G., Marvaso, G., Ferrara, R., Russo, G. L., Gugliandolo, S. G., Piperno, G., Spaggiari, L., de Marinis, F., Orecchia, R., Garassino, M. C., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.017 · Cited by 27
Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma
Lee, B. M., & Seong, J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i10.919 · Cited by 27
Petersen, S. H., Kua, L., Nakajima, S., Yong, W. P., & Kono, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-91603-7 · Cited by 27
Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A., & Ito, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0939 · Cited by 26
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?
Samuels, S. E., Eisbruch, A., Beitler, J. J., Corry, J. F., Bradford, C. R., Saba, N. F., van den Brekel, M. W. M., Smee, R., Strojan, P., Suarez, C. M., et al. (2015) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-015-3771-x · Cited by 26
Immunotherapy for Malignant Pleural Mesothelioma. Current Status and Future Prospects
Wong, R. M. H., Ianculescu, I., Sharma, S. P., Gage, D. L., Olevsky, O. M., Kotova, S., Kostic, M. N., Grundfest, W. S., Hou, D., & Cameron, R. B. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0472tr · Cited by 26
Damiana, T. S. T., & Dalm, S. U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050674 · Cited by 26
Zhang, R., Kang, J., Ren, S., Xing, L., & Xu, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6256 · Cited by 26
Radiation dose and schedule influence the abscopal effect in a bilateral murine CT26 tumor model
Nazari, H. G., Alimohammadi, M., Alimohammadi, R., Rostami, E., Bakhshandeh, M., Webster, T. J., Chalbatani, G. M., Tavakkol‐Afshari, J., & Jalali, S. A. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108737 · Cited by 26
van Luijk, I. F., Smith, S. M., Ojeda, M. C. M., Oei, A. L., Kenter, G. G., & Jordanova, E. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092277 · Cited by 26
Effect of stereotactic radiotherapy on immune microenvironment of lung cancer
Xiao, Y., & Zhuang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025872 · Cited by 26
Zhao, L., Chen, X., Wu, H., He, Q., Ding, L., & Yang, B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115724 · Cited by 26
Lim, J. Y. H., Brockstedt, D. G., Lord, E. M., & Gerber, S. A. (2014) · OncoImmunology · doi:10.4161/onci.29028 · Cited by 26
Role of Immunotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer
Rijavec, E., Genova, C., Alama, A., Barletta, G., Sini, C., Pronzato, P., Coco, S., Bello, M. G. D., Savarino, G., Truini, A., et al. (2013) · Future Oncology · doi:10.2217/fon.13.145 · Cited by 26
Abscopal effect in metastatic renal cell carcinoma
de Walle, M. V., Demol, J., Staelens, L., & Rottey, S. (2016) · Acta Clinica Belgica · doi:10.1080/17843286.2016.1201614 · Cited by 26
Alexander, G. S., Palmer, J. D., Tuluc, M., Lin, J., Dicker, A. P., Bar‐Ad, V., Harshyne, L. A., Louie, J., Shaw, C. M., Hooper, D. C., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0328-4 · Cited by 26
Kumar, S. S., Higgins, K. A., & McGarry, R. C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00197 · Cited by 26
Combining immunotherapy with radiation therapy in thoracic oncology
Badiyan, S. N., Roach, M. C., Chuong, M. D., Rice, S. R., Onyeuku, N. E., Remick, J. S., Chilukuri, S. C., Glass, E., Mohindra, P., & Simone, C. B. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.73 · Cited by 26
Wang, K., Zhu, G., Shi, Y., Li, Z.-Y., Zhang, X., & Li, H.-Y. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.10.010 · Cited by 26
Harnessing the potential of multimodal radiotherapy in prostate cancer
Philippou, Y., Sjoberg, H. T., Lamb, A. D. G., Camilleri, P., & Bryant, R. J. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0310-3 · Cited by 26
Boutros, C., Chaput, N., Lanoy, É., Larive, A., Mateus, C., Routier, É., Sun, R., Tao, Y. G., Massard, C., Bahleda, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000627 · Cited by 26
Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine
Hagan, C. T., Mi, Y., Knape, N. M., & Wang, A. Z. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00520 · Cited by 26
Ni, J., Zhou, Y., Wu, L., Ai, X., Dong, X., Chu, Q., Han, C., Wang, X., & Zhu, Z. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01905-3 · Cited by 26
High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy
Ota, N., Yoshimoto, Y., Darwis, N. D. M., Sato, H., Ando, K., Oike, T., & Ohno, T. (2021) · Japanese Journal of Radiology · doi:10.1007/s11604-021-01230-5 · Cited by 26
APLP2 regulates the expression of MHC class I molecules on irradiated Ewing’s sarcoma cells
Peters, H. L., Yan, Y., & Solheim, J. C. (2013) · OncoImmunology · doi:10.4161/onci.26293 · Cited by 26
Michelini, R. H., Freschi, M., Manzo, T., Jachetti, E., Degl'Innocenti, E., Grioni, M., Basso, V., Bonini, C., Simpson, E., Mondino, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4253 · Cited by 26
GRIM-19 inhibits the STAT3 signaling pathway and sensitizes gastric cancer cells to radiation
Bu, X., Zhao, C., Wang, W., & Zhang, N. (2012) · Gene · doi:10.1016/j.gene.2012.10.057 · Cited by 26
Immunological signatures from irradiated cancer-associated fibroblasts
Berzaghi, R., Gundersen, K., Pedersen, B. D., Utne, A., Yang, N., Hellevik, T., & Martínez-Zubiaurre, I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433237 · Cited by 27
High versus low dose irradiation for tumor immune reprogramming
de Olza, M. O., Bourhis, J., Irving, M. B., Coukos, G., & Herrera, F. G. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.08.001 · Cited by 25
Yi, X.-F., Gao, R.-L., Sun, L., Wu, Z.-X., Zhang, S., Huang, L., Han, C., & Ma, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114770 · Cited by 25
Exploring low-dose radiotherapy to overcome radio-immunotherapy resistance
Wang, J., Zhang, J., Wen, W., Wang, F., Wu, M., Chen, D., & Yu, J. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166789 · Cited by 25
Huang, K. C., Chen, W. T.-L., Chen, J., Lee, C., Wu, C.-H., Lai, C.-Y., Yang, P.-C., Liang, J., Shiau, A., Chao, K. S. C., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00881-5 · Cited by 25
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors
Holtermann, A., Gislon, M., Angele, M. K., Subklewe, M. S., von Bergwelt‐Baildon, M., Lauber, K., & Kobold, S. (2024) · BioDrugs · doi:10.1007/s40259-024-00669-y · Cited by 25
Cruz, L. M. D. L., Nocera, N. F., & Czerniecki, B. J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0052 · Cited by 25
Radiotherapy in the age of cancer immunology: Current concepts and future developments
Loi, M., Desideri, I., Greto, D., Mangoni, M., Sottili, M., Meattini, I., Becherini, C., Terziani, F., Paoli, C. D., Olmetto, E., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.002 · Cited by 25
Friedman, J., Padget, M. R., Lee, J., Schlom, J., Hodge, J. W., & Allen, C. T. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.01.017 · Cited by 25
Self-citationElsayad, K., Stadler, R., Steinbrink, K., & Eich, H. T. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14044 · Cited by 25
The Combined Use of SBRT and Immunotherapy—a Literature Review
Lubas, M. J., & Kumar, S. S. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00986-9 · Cited by 25
The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?
Yin, T., Xin, H., Yu, J., & Teng, F. (2021) · Biomarker Research · doi:10.1186/s40364-021-00277-w · Cited by 25
Goff, P. H., Bhakuni, R., Pulliam, T. H., Lee, J. H., Hall, E. T., & Nghiem, P. (2021) · Cancers · doi:10.3390/cancers13143415 · Cited by 25
Low-dose irradiation for reversing immunotherapy resistance: how to translate?
Ochoa-de-Olza, M., Bourhis, J., Coukos, G., & Herrera, F. G. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004939 · Cited by 25
Lyu, L., Yi, M., Chen, J., Zhang, J., Ma, X., Zhang, X., Zeng, L., Xue, Y., Wen, H., Deng, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202501819 · Cited by 24
Expected Paradigm Shift in Brain Metastases Therapy—Immune Checkpoint Inhibitors
Jindal, V., & Gupta, S. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0905-3 · Cited by 24
Pieper, A. A., Zangl, L. M., Speigelman, D. V., Feils, A. S., Hoefges, A., Jagodinsky, J. C., Felder, M. A. R., Tsarovsky, N. W., Arthur, I. S., Brown, R. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763888 · Cited by 24
Biondetti, P., Saggiante, L., Ierardi, A. M., Iavarone, M. A., Sangiovanni, A., Pesapane, F., Fumarola, E. M., Lampertico, P., & Carrafiello, G. (2021) · Cancers · doi:10.3390/cancers13225797 · Cited by 24
Deng, S., Wang, J., Hu, Y., Sun, Y., Yang, X., Zhang, B., Deng, Y., Wei, W., Zhang, Z., Wen, L., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216898 · Cited by 24
Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy
Liu, J., Li, B., Li, L., Ming, X., & Xu, Z. P. (2024) · Small · doi:10.1002/smll.202403024 · Cited by 24
Shibamoto, Y., Okamoto, M., Kobayashi, M., Ayakawa, S., Iwata, H., SUGIE, C., Mitsuishi, Y., & Takahashi, H. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.108 · Cited by 24
Eljalby, M., Pannullo, S. C., Schwartz, T. H., Parashar, B., & Wernicke, A. G. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.04.093 · Cited by 24
Aydin, Ö. F., Chandran, P., Lorsung, R. M., Cohen, G., Burks, S. R., & Frank, J. A. (2019) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2019.08.014 · Cited by 24
Lin, J., Guo, Q., Guo, Z., Lu, T., Chen, G., Lin, S., Chen, M., Chen, C., Lu, J., Zong, J., et al. (2022) · Radiation Oncology · doi:10.1186/s13014-022-02073-8 · Cited by 24
Radiotherapy and Immunotherapy: Improving Cancer Treatment through Synergy
Reynders, K., & Ruysscher, D. D. (2015) · Progress in tumor research · doi:10.1159/000437185 · Cited by 24
Zhou, C., & Zhang, J. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0685-9 · Cited by 24
Michelin, S., Gallegos, C. E., Dubner, D., Favier, B., & Carosella, E. D. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.07.030 · Cited by 24
Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers
Elbehi, M. A., I, A. R., Ekine-Afolabi, B. A., & Cash, E. D. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104977 · Cited by 23
Aboudaram, A., Chaltiel, L., Pouessel, D., Graff-Cailleaud, P., Benziane-Ouaritini, N., Sargos, P., Schick, U., Créhange, G., Moyal, E. C., Chevreau, C., et al. (2023) · Cancers · doi:10.3390/cancers15041161 · Cited by 23
Dai, D., Li, X., Zhuang, H., Ling, Y., Chen, L., Cheng, L., Zhang, J., Wang, Y., Li, Y., Tang, H., et al. (2024) · Advanced Science · doi:10.1002/advs.202308174 · Cited by 23
Rafiq, Z., Kang, M., Barsoumian, H. B., Manzar, G. S., Hu, Y. H., Leuschner, C., Huang, A., Masrorpour, F., Lu, W., Puebla‐Osorio, N., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03281-2 · Cited by 23
Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab
Kropp, L. M., Santos, J. F. D. L., McKee, S. B., & Conry, R. M. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000142 · Cited by 23
Pastina, P., Nardone, V., Botta, C., Croci, S., Tini, P., Battaglia, G., Ricci, V., Cusi, M. G., Gandolfo, C., Misso, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20411 · Cited by 23
Repetto‐Llamazares, A. H. V., Malenge, M. M., O’Shea, A., Eiríksdóttir, B., Stokke, T., Larsen, R. H., & Dahle, J. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13139 · Cited by 23
Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade
Heath, B. R., Michmerhuizen, N. L., Donnelly, C. R., Sansanaphongpricha, K., Sun, D., Brenner, J. C., & Lei, Y. L. (2019) · Journal of Dental Research · doi:10.1177/0022034519864112 · Cited by 23
Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer
Ratnayake, G., Shanker, M., Roberts, K. E., Mason, R., Hughes, B. G. M., Lwin, Z., Jain, V. K. S., O'Byrne, K. J., Lehman, M., & Chua, B. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13242 · Cited by 23
Plavc, G., & Strojan, P. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0060 · Cited by 23
Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel
Brouwer, T. P., Vahrmeijer, A. L., & de Miranda, N. F. C. C. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00587-z · Cited by 23
The adaptive immune response to colorectal cancer: From the laboratory to clinical practice
Curtis, N. J., Primrose, J. M., Thomas, G. J., Mirnezami, A. H., & Ottensmeier, C. H. H. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.05.011 · Cited by 23
Immunotherapy of MHC Class I-Deficient Tumors
Reiniš, M. (2010) · Future Oncology · doi:10.2217/fon.10.128 · Cited by 23
Hillman, G. G., Reich, L. A., Rothstein, S. E., Close, L. A., Fountain, M. D., Hankerd, K., Yunker, C. K., Rakowski, J., Quéméneur, É., & Slos, P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0204-3 · Cited by 23
Radiotherapy in combination with immune checkpoint inhibitors
Ruysscher, D. D., Reynders, K., Limbergen, E. J. V., & Lambrecht, M. L. F. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000352 · Cited by 23
State-of-the-Art Management of Renal Cell Carcinoma
Mourad, W. F., Dutcher, J. P., & Ennis, R. D. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31825d5522 · Cited by 23
Vaccination therapy in prostate cancer
Marrari, A., Iero, M., Pilla, L., Villa, S., Salvioni, R., Valdagni, R., Parmiani, G., & Rivoltini, L. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0233-8 · Cited by 23
Merhi, M., Raza, A., Inchakalody, V. P., Siveen, K. S., Kumar, D., Sahir, F., Mestiri, S., Hydrose, S., Allahverdi, N., Jalis, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001278 · Cited by 22
Rallis, K. S., Hillyar, C., Sideris, M. C., & DAVIES, J. K. (2021) · Anticancer Research · doi:10.21873/anticanres.14871 · Cited by 22
Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer
Polten, R., Kutle, I., Hachenberg, J., Klapdor, R., Morgan, M. A., & Schambach, A. (2022) · Cancers · doi:10.3390/cancers15010263 · Cited by 22
RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma
Lambing, S., Tan, Y. P., Vasileiadou, P., Holdenrieder, S., Müller, P., Hagen, C., Garbe, S., Behrendt, R., Schlee, M., van den Boorn, J. G., et al. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad001 · Cited by 23
Guberina, N., Wirsdörfer, F., Stuschke, M., & Jendrossek, V. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100892 · Cited by 22
Immune effects of α and β radionuclides in metastatic prostate cancer
Lunj, S., Smith, T., Reeves, K. J., Currell, F. J., Honeychurch, J., Hoskin, P., & Choudhury, A. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00924-5 · Cited by 22
Metadata
- Authors
- Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., & Neefjes, J. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- 2Laboratory of Tumor Immunology and Biology
- National Institutes of Health (US)
- 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, and Centre for Medical Systems Biology, 2333 2A Leiden, Netherlands
- Leiden University Medical Center (NL)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-04-24
- Volume
- 203
- Issue
- 5
- Pages
- 1259-1271
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3212727
- OpenAlex
- W2127733313
- Cited by
- 1,737
- References
- 53
- Citations by year
- 2026: 88 · 2025: 116 · 2024: 119 · 2023: 128 · 2022: 149 · 2021: 174 · 2020: 154 · 2019: 118 · 2018: 112 · 2017: 113 · 2016: 78 · 2015: 71 · 2014: 67 · 2013: 62 · 2012: 41
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- radiotherapy, gamma irradiation, MHC class I expression, antigen presentation, protein degradation, mTOR signaling, translation (biology), cytotoxic T lymphocytes, cancer immunotherapy, colon adenocarcinoma
- MeSH terms
- Adenocarcinoma, Animals, Colonic Neoplasms, Dose-Response Relationship, Radiation, Gamma Rays, Humans, Immunotherapy, Mice, Transgenic, Peptides, Protein Kinases, Radiotherapy, T-Lymphocytes, Cytotoxic, Protein Biosynthesis, HLA-A2 Antigen, Gene Expression Regulation, Neoplastic, Antigen Presentation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.